Expert discusses the benefits of IPP in improving health care utilization
“One of our early findings showed that males who have IPPs use less depression medication, have less emergency room visits, and have less clinic visits for psychiatry-related conditions,” says Roei Golan.
In this video, Roei Golan highlights the background and key findings from the study, “Improved healthcare utilization among men with depression undergoing inflatable penile prosthesis in a United States commercial population,” which he presented at the 24th Annual Fall Scientific Meeting of Sexual Medicine Society of North America in San Diego, California. Golan is a medical student at Florida State University College of Medicine in Tallahassee, Florida.
Video Transcript:
We looked at a very unique database called the IBM MarketScan database, which is a private database, it's very expensive to access. We were able to get help from Boston Scientific, who helped us access the database and analyze the data from there. Essentially, what we wanted to see was can penile implants benefit men and benefit health care costs. For example, if a man turned 65, and he gets an implant, does that make him use the emergency room less? Does that make him use medications for depression less? Does that make him use medications for diabetes less? Does it make him lose weight? Factors like that. The reason we wanted to look into it was to show that, yes, it costs a decent amount of money for males to get IPP, penile implants, but we do believe that it can benefit these males. So, what we're trying to do is we're trying to show how it can benefit it. One of our early findings showed that males who have IPPs use less depression medication, have less emergency room visits, and have less clinic visits for psychiatry-related conditions, which is a pretty cool finding.
This transcription has been edited for clarity.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
